Truist Securities Rates Guardian Pharmacy Services (GRDN) buy

Truist Securities maintains its positive stance on Guardian Pharmacy Services as the healthcare stock changes hands near $42.42, a 10.80% upside from the current price.

By EarningsIQ Research Desk · Published Jun 17, 2026, 11:01 AM EDT · Updated Jun 18, 2026, 2:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Truist Securities rated Guardian Pharmacy Services, Inc. ($GRDN) "buy" with a $47 price target on June 17, 2026.

Since the rating, $GRDN is down 11.7% after 1 week, down 6.6% after 1 month and down 9.1% to date (from the $43.40 close on Jun 17, 2026).

GRDN Guardian Pharmacy Services, Inc.

$39.47 +33.66% year to date

Daily close · Oct 16, 2026

Key Points

Truist Securities analyst David Macdonald reiterated a buy rating on Guardian Pharmacy Services on June 17, 2026, setting a $47 price target.
Truist Securities's $47 price target implies 10.80% upside from Guardian Pharmacy Services, Inc.'s ($GRDN) current $42.42 share price.
Guardian Pharmacy Services shares recently traded at $42.42, sitting well above their 200-day moving average of $36.59.
Other Wall Street firms including Keybanc and Oppenheimer have also updated their views on the stock in recent months.

Get $GRDN trade alerts by text

We text you when insiders, Congress or big funds trade $GRDN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Guardian Pharmacy Services, Inc. alert may contain errors. Disclosures

Truist Securities Reiterates Support for Guardian Pharmacy Services

Truist Securities reaffirmed its positive outlook on Guardian Pharmacy Services (NYSE: GRDN) on June 17, 2026. Analyst David Macdonald kept a buy rating on the healthcare provider with a price target of $47.00. The firm's ongoing support points to confidence in the company's long-term business model within the medical care facilities sector.

Guardian Pharmacy Services Stock Moves Near Key Averages

Guardian Pharmacy Services shares recently changed hands at $42.42 on Wednesday. The stock has experienced a busy trading range over the past year, falling as low as $23.14 and climbing as high as $48.33. The current price sits well above both its 50-day moving average of $40.57 and its 200-day moving average of $36.59, showing steady momentum for the pharmacy service provider.

12-month forecast

$GRDN price target

Guardian Pharmacy Services, Inc. daily closes and this analyst's $47 target. Not advice.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on Guardian Pharmacy Services over recent months, updating targets and ratings. On September 23, 2026, Keybanc initiated coverage on the stock with an overweight rating and a $52.00 price target. Earlier in the month on September 21, 2026, Truist Securities maintained its buy rating while lifting its target from $47.00 to $51.00. Oppenheimer also maintained an outperform rating on August 7, 2026, moving its target from $43.00 to $49.00. Across the broader analyst community, the stock holds a consensus strong buy recommendation with a mean price target of $49.50 based on six analyst opinions.

Inside Guardian Pharmacy Services Operations

Founded in 2003 and based in Atlanta, Georgia, Guardian Pharmacy Services operates as a pharmacy service company providing technology-enabled solutions for long-term care facilities across the United States. The company helps residents in assisted living facilities, behavioral health facilities, and group homes by managing clinical care and drug dispensing needs. Its proprietary tools include Guardian Compass dashboards, GuardianShield programs, Order Entry QA Analyzers, and Medication Spend Analyzers to help local pharmacies track operations and optimize monthly drug spending.

Looking Ahead to Upcoming Milestones

Investors tracking Guardian Pharmacy Services can look ahead to the company's next scheduled earnings report, which is expected on November 9, 2026. Market participants will monitor whether the company's recent revenue growth and profitability metrics align with the higher expectations set by covering analysts.